MedTrace Logo

A Safety and Efficacy Study of Abicipar Pegol in Participants With Neovascular Age-related Macular Degeneration

NCT02462928 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 939

Last updated 2020-07-28

Study results available
· View outcomes & findings →

Summary

This is a safety and efficacy study of abicipar pegol in participants with neovascular age-related macular degeneration.

Conditions

  • Macular Degeneration

Interventions

DRUG

Abicipar Pegol

Abicipar pegol intravitreal injection.

DRUG

Ranibizumab

Ranibizumab intravitreal injection.

OTHER

Sham Procedure

Sham injection.

Sponsors & Collaborators

  • Allergan

    lead INDUSTRY

Principal Investigators

  • Joanne Li · Allergan

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-06-25
Primary Completion
2018-04-18
Completion
2019-06-19
FDA Drug
Yes

Countries

  • United States
  • Argentina
  • Austria
  • Chile
  • Colombia
  • Czechia
  • France
  • Germany
  • Hong Kong
  • Israel
  • Latvia
  • New Zealand
  • Philippines
  • Singapore
  • South Korea
  • Spain
  • Switzerland

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02462928 on ClinicalTrials.gov